Featured on Homepage

19 08, 2022

Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial

2022-08-19T18:58:40+00:00August 19th, 2022|

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to [...]

7 01, 2022

A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults

2022-01-07T20:35:12+00:00January 7th, 2022|

Pharmaceutical companies have used experimental models of transient insomnia to assess the sleep-promoting effects of investigational drugs for over 40 years.  These models have included the "first-night effect" model, a parallel-group design that assessed drug effects when sleep was recorded in normal, healthy subjects who slept in a new or novel environment for the [...]

7 06, 2021

Clinilabs Drug Development Corporation Joins Decentralized Trials & Research Alliance (DTRA) to Accelerate Clinical Trials

2021-06-08T16:27:28+00:00June 7th, 2021|

Clinilabs and the DTRA Aim to Dramatically Increase Access for All Patient Populations in Clinical Trials and Research June 7, 2021 – Clinilabs Drug Development Corporation joins a historic alliance of over one hundred life science and healthcare organizations that seek to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized [...]

12 05, 2021

Clinilabs congratulates Larimar Therapeutics Inc. on their Topline Phase 1 Clinical Trial Data in patients with Friedreich’s Ataxia

2021-05-24T20:04:46+00:00May 12th, 2021|

Clinilabs congratulates Larimar Therapeutics Inc. on their Topline Phase 1 Clinical Trial Data in patients with Friedreich’s Ataxia! We are proud to have been part of this clinical trial and to have worked with this partner who is dedicated to bringing life changing treatments to patients with this rare disease. To learn more about [...]

19 02, 2021

With a Pandemic Push, DCTs Are a ‘Virtual’ Lock to Go Big in ‘21

2021-02-22T20:14:00+00:00February 19th, 2021|

2020 will go down as a miserable year, but beyond the heartache, some developments may represent bright spots that light the way to the future. One of these is the growth of Decentralized Clinical Trials (DCTs). DCTs are virtual trials that integrate remote assessments with modern digital health technologies, including remote rating apps, wearable monitoring [...]

1 12, 2020

T3D Therapeutics selects Clinilabs Drug Development Corporation as contract research organization partner for Phase 2 trial of T3D-959 in patients with Alzheimer’s Disease.

2020-12-01T21:41:09+00:00December 1st, 2020|

T3D Therapeutics, Inc. (“T3D Therapeutics” or the “Company”), a biopharmaceutical company specializing in the development of ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease and other neurodegenerative diseases, announced it has engaged Clinilabs Drug Development Corporation (“Clinilabs”) as the contract research organization (“CRO”) for its upcoming phase 2 trial of T3D-959 named the PIONEER [...]

10 03, 2020

Supporting Our Patients and Research Subjects Amidst COVID-19 Concerns

2020-04-15T19:17:29+00:00March 10th, 2020|

By now, you have likely heard about the Coronavirus (officially called “2019-Novel Coronavirus” or “COVID-19”) in the news. While the immediate health risk remains low to Americans, there are still ways that all of us can play a role in helping to prevent the spread of this and other viruses. With that said, Clinilabs, the [...]

20 02, 2020

Clinilabs Drug Development Corporation Achieves CNS Trial Start-Up in 1/3 the Time of Industry Standard

2020-02-27T16:24:07+00:00February 20th, 2020|

Clinilabs Drug Development Corporation, the only global, full-service contract research organization (CRO) focused exclusively on central nervous system (CNS) drug development, was engaged by a large, clinical-stage biopharmaceutical company to manage a randomized, double-blind, placebo-controlled study of a therapy for patients with acute migraine headache. The pivotal trial, involving 100 sites, various demographics and [...]

22 01, 2020

Clinilabs Reduces Patient Outreach Time by 85%

2020-01-27T23:53:08+00:00January 22nd, 2020|

Clinilabs Drug Development Corporation, a mid-sized, full-service CRO that provides a full range of clinical drug development services, has been utilizing Facebook advertising as an essential tool for generating study participant leads with good success. In fact, Facebook recruitment has been one of Clinilabs’ fastest responding and lowest cost recruitment tools. But even with the [...]

17 10, 2019

Clinilabs Drug Development Corporation and SureClinical Announce Global Lunch & Learn Series for Clinical Operations

2020-01-22T18:13:49+00:00October 17th, 2019|

Clinilabs Drug Development Corporation, a CNS-focused contract research organization, and SureClinical, a global provider of innovative cloud solutions for the health sciences market, are sponsoring a global Lunch & Learn series demonstrating how sponsors can streamline and accelerate the clinical trials process. Focusing on real-world examples, Clinilabs will reveal strategies that cut their site initiation [...]